Fondation A De Rothschild
- Address
- lock Available on a paid plan
Fondation A De Rothschild - Advanced Neurological and Ophthalmological Research
Fondation A De Rothschild is a distinguished medical research institution specializing in cutting-edge neurological and ophthalmological conditions. The center demonstrates exceptional expertise in acute stroke management, with multiple trials investigating novel interventions including endovascular therapy, thrombolytic agents, and innovative approaches for both anterior and posterior circulation strokes. Their comprehensive stroke program addresses critical care challenges from the acute phase through long-term anticoagulation management following intracerebral hemorrhage.
- Advanced retinal disorders: age-related macular degeneration, diabetic macular edema, retinal vein occlusions, geographic atrophy, and pediatric retinoblastoma
- Complex neuroimmunological diseases: multiple sclerosis (relapsing-remitting and primary progressive), myasthenia gravis, and neuromyelitis optica spectrum disorders
- Rare neurological conditions: diffuse midline gliomas (DIPG), Tourette's disorder, Wilson's disease, and chronic inflammatory demyelinating polyneuropathy
- Cerebrovascular emergencies: subarachnoid hemorrhage management, vasospasm treatment, and arteriovenous malformations
The center's ophthalmology research portfolio is particularly robust, encompassing innovative drug delivery systems such as the Port Delivery System for sustained ranibizumab release, novel anti-VEGF therapies, and complement inhibition strategies. Their work in inflammatory conditions extends to uveitis in Behçet's disease, non-infectious uveitis, and acute anterior ischemic optic neuropathy. The center also maintains active programs in neurodegenerative research, including Alzheimer's disease therapeutic trials and epilepsy management with next-generation antiepileptic medications. Their commitment to rare disease research and precision medicine approaches positions them as a leader in both neurological and ophthalmological translational research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 90 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 81 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 26 by active trials.
- 1Fondation A De Rothschild8active
lock +25 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondation A De Rothschild12trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fondation A De Rothschild
lock Showing 1 of 74 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4) | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 90 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorescein Sodium | 6 | Unknown | 2022-12-21 | 2026-06-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.